Oraya's AMD device reduces drug use at two years
This article was originally published in Clinica
Executive Summary
Oraya Therapeutics has reported more favorable data for its device designed to treat wet age-related macular degeneration (AMD) in a one-off procedure and which could potentially rival drugs such as Roche/Novartis’s market-leading anti-VEGF therapy Lucentis (ranibizumab).